{
  "ProtocolSection": {
    "IdentificationModule": {
      "NCTId": "NCT03874572",
      "OrgStudyIdInfo": {
        "OrgStudyId": "CVB2018-2"
      },
      "SecondaryIdInfoList": {
        "SecondaryIdInfo": [
          {
            "SecondaryId": "2018-003856-19",
            "SecondaryIdType": "EudraCT Number"
          }
        ]
      },
      "Organization": {
        "OrgFullName": "Rigshospitalet, Denmark",
        "OrgClass": "OTHER"
      },
      "BriefTitle": "Allogeneic Mesenchymal Stem Cells for Radiation-induced Hyposalivation and Xerostomia/Dry Mouth",
      "OfficialTitle": "A Phase I Open Label Study Evaluating the Safety and Feasibility of Allogeneic Mesenchymal Stem Cells for Radiation-induced Hyposalivation and Xerostomia in Previous Oropharynx Cancer Patients",
      "Acronym": "MESRIX-SAFETY"
    },
    "StatusModule": {
      "StatusVerifiedDate": "September 2020",
      "OverallStatus": "Active, not recruiting",
      "ExpandedAccessInfo": {
        "HasExpandedAccess": "No"
      },
      "StartDateStruct": {
        "StartDate": "March 18, 2019",
        "StartDateType": "Actual"
      },
      "PrimaryCompletionDateStruct": {
        "PrimaryCompletionDate": "June 22, 2020",
        "PrimaryCompletionDateType": "Actual"
      },
      "CompletionDateStruct": {
        "CompletionDate": "December 1, 2025",
        "CompletionDateType": "Anticipated"
      },
      "StudyFirstSubmitDate": "March 12, 2019",
      "StudyFirstSubmitQCDate": "March 12, 2019",
      "StudyFirstPostDateStruct": {
        "StudyFirstPostDate": "March 14, 2019",
        "StudyFirstPostDateType": "Actual"
      },
      "LastUpdateSubmitDate": "January 27, 2021",
      "LastUpdatePostDateStruct": {
        "LastUpdatePostDate": "January 29, 2021",
        "LastUpdatePostDateType": "Actual"
      }
    },
    "SponsorCollaboratorsModule": {
      "ResponsibleParty": {
        "ResponsiblePartyType": "Principal Investigator",
        "ResponsiblePartyInvestigatorFullName": "Charlotte Lynggaard",
        "ResponsiblePartyInvestigatorTitle": "Principal Investigator",
        "ResponsiblePartyInvestigatorAffiliation": "Rigshospitalet, Denmark"
      },
      "LeadSponsor": {
        "LeadSponsorName": "Rigshospitalet, Denmark",
        "LeadSponsorClass": "OTHER"
      }
    },
    "OversightModule": {
      "OversightHasDMC": "Yes",
      "IsFDARegulatedDrug": "No",
      "IsFDARegulatedDevice": "No"
    },
    "DescriptionModule": {
      "BriefSummary": "An investigator-initiated, non-randomized, open label study to investigate the safety, feasibility and tolerability of intraglandular injection of allogeneic mesenchymal stem/stromal cells (MSCs) into the submandibular and parotid glands of the patients with radiation-induced hyposalivation and xerostomia after radiation for a oropharyngeal squamous cell carcinoma",
      "DetailedDescription": "Patients with previous oropharyngeal cancer and radiation-induced hyposalivation and xerostomia (dry mouth syndrome) will receive intraglandular injections of allogeneic adipose-derived MSCs into the submandibular and parotid glands. The trial will be Good Clinical Practice (GCP) Monitored. From healthy donors, MSCs will be produced at a Good Manufacturing Practice (GMP) Facility.\n\nThe patients will be followed for four months for safety, tolerability, and efficacy registration. Changes in quality of life, unstimulated, and stimulated whole saliva flow rate, salivary gland function will be assessed. Immune response towards receiving allogeneic MSCs will be evaluated in plasma and saliva. Changes in the composition and quality of the whole saliva will be investigated.\n\nSaliva from the participants will altså be compared to saliva from ten healthy controls."
    },
    "ConditionsModule": {
      "ConditionList": {
        "Condition": [
          "Xerostomia Due to Radiotherapy",
          "Hyposalivation",
          "Xerostomia",
          "Oropharynx Cancer",
          "Salivary Gland Diseases",
          "Dry Mouth",
          "Mesenchymal Stem Cells",
          "Mesenchymal Stromal Cells",
          "Stem Cells"
        ]
      },
      "KeywordList": {
        "Keyword": [
          "Xerostomia Due to Radiotherapy"
        ]
      }
    },
    "DesignModule": {
      "StudyType": "Interventional",
      "PhaseList": {
        "Phase": [
          "Phase 1"
        ]
      },
      "DesignInfo": {
        "DesignAllocation": "N/A",
        "DesignInterventionModel": "Single Group Assignment",
        "DesignPrimaryPurpose": "Treatment",
        "DesignMaskingInfo": {
          "DesignMasking": "None (Open Label)"
        }
      },
      "EnrollmentInfo": {
        "EnrollmentCount": "10",
        "EnrollmentType": "Actual"
      }
    },
    "ArmsInterventionsModule": {
      "ArmGroupList": {
        "ArmGroup": [
          {
            "ArmGroupLabel": "Allogeneic mesenchymal stem/stromal cell therapy",
            "ArmGroupType": "Experimental",
            "ArmGroupDescription": "Treatment with intra-glandular Injections of allogeneic adipose derived stem cells",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Biological: Allogeneic adipose derived stem/stromal cells"
              ]
            }
          }
        ]
      },
      "InterventionList": {
        "Intervention": [
          {
            "InterventionType": "Biological",
            "InterventionName": "Allogeneic adipose derived stem/stromal cells",
            "InterventionDescription": "Culture expanded allogeneic adipose derived stem/stromal cells",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "Allogeneic mesenchymal stem/stromal cell therapy"
              ]
            }
          }
        ]
      }
    },
    "OutcomesModule": {
      "PrimaryOutcomeList": {
        "PrimaryOutcome": [
          {
            "PrimaryOutcomeMeasure": "Safety: Number of patients with serious adverse events",
            "PrimaryOutcomeDescription": "Registration of number of patients with serious adverse events in a 4 months follow-up period",
            "PrimaryOutcomeTimeFrame": "4 months"
          }
        ]
      },
      "SecondaryOutcomeList": {
        "SecondaryOutcome": [
          {
            "SecondaryOutcomeMeasure": "Immune reponse :Development of donor specific antibodies",
            "SecondaryOutcomeDescription": "Registration of development of tissue antibodies towards donor cells",
            "SecondaryOutcomeTimeFrame": "4 months"
          },
          {
            "SecondaryOutcomeMeasure": "Efficacy: Change in Unstimulated Whole Salivary flow rate",
            "SecondaryOutcomeDescription": "Unstimulated whole saliva flow rate is assessed by sialometry",
            "SecondaryOutcomeTimeFrame": "4 months"
          },
          {
            "SecondaryOutcomeMeasure": "Efficacy: Change in Stimulated Whole Salivary flow rate",
            "SecondaryOutcomeDescription": "Unstimulated whole saliva flow rate is assessed by sialometry",
            "SecondaryOutcomeTimeFrame": "4 months"
          },
          {
            "SecondaryOutcomeMeasure": "Efficacy: Change in quality of life",
            "SecondaryOutcomeDescription": "Change in quality of life evaluted by QLQ-H&N-35 and XQ questionnaires",
            "SecondaryOutcomeTimeFrame": "4 months"
          },
          {
            "SecondaryOutcomeMeasure": "Efficacy: Salivary gland function",
            "SecondaryOutcomeDescription": "Assessed by salivary gland 99mTc scintigraphy",
            "SecondaryOutcomeTimeFrame": "4 months"
          },
          {
            "SecondaryOutcomeMeasure": "Efficacy: Change in Saliva composition",
            "SecondaryOutcomeDescription": "Change in inorganic saliva composition",
            "SecondaryOutcomeTimeFrame": "4 months"
          },
          {
            "SecondaryOutcomeMeasure": "Efficacy: Change in Saliva Proteomics",
            "SecondaryOutcomeDescription": "Change in Saliva proteomics",
            "SecondaryOutcomeTimeFrame": "4 months"
          },
          {
            "SecondaryOutcomeMeasure": "Efficacy: Change in RNA in Saliva",
            "SecondaryOutcomeDescription": "Change in RNA in saliva",
            "SecondaryOutcomeTimeFrame": "4 months"
          },
          {
            "SecondaryOutcomeMeasure": "Immune reponse",
            "SecondaryOutcomeDescription": "Reactions in plasma and saliva will be assessed",
            "SecondaryOutcomeTimeFrame": "4 months"
          }
        ]
      }
    },
    "EligibilityModule": {
      "EligibilityCriteria": "Inclusion Criteria:\n\nAge between 18-75 years\nPrevious radiotherapy +/- chemotherapy for OPSCC stage I- II (UICC-8, 2017)\n2 years' follow-up without recurrence\nClinically reduced salivation and hyposalivation, evaluated by a screening\nUnstimulated salivary flow rate between 0.2mL/min and 0.05mL/min\nGrade 2-3 xerostomia (CTCAEv5.0)\nWHO Performance status (PS) 0-1\nInformed consent\n\nExclusion Criteria:\n\nAny cancer in the previous 4 years (not including OPSCC and basocellular carcinomas)\nXerogenic medications\nPenicillin or Streptomycin allergy\nAny other diseases of the salivary glands, e.g. Sjögren's syndrome or sialolithiasis\nPrevious parotid or submandibular gland surgery\nPrevious treatment with any type of stem cells\nBreastfeeding, Pregnancy or planned pregnancy within the next 2 years\nSmoking within the previous 6 months.\nAlcohol abuse (consumption must not exceed 7 units/week for women and 14 units/week for men (Danish National board health alcohol guidelines3)\nAny other disease/condition judged by the investigator to be grounds for exclusion",
      "HealthyVolunteers": "Accepts Healthy Volunteers",
      "Gender": "All",
      "MinimumAge": "18 Years",
      "MaximumAge": "75 Years",
      "StdAgeList": {
        "StdAge": [
          "Adult",
          "Older Adult"
        ]
      }
    },
    "ContactsLocationsModule": {
      "OverallOfficialList": {
        "OverallOfficial": [
          {
            "OverallOfficialName": "Charlotte Lynggaard, MD",
            "OverallOfficialAffiliation": "Department of Otolaryngology, Rigshospitalet, University Hospital of Copenhagen",
            "OverallOfficialRole": "Principal Investigator"
          }
        ]
      },
      "LocationList": {
        "Location": [
          {
            "LocationFacility": "Department of Otolaryngology, Rigshospitalet, University Hospital of Copenhagen",
            "LocationCity": "Copenhagen",
            "LocationZip": "2100",
            "LocationCountry": "Denmark"
          },
          {
            "LocationFacility": "Department of Otolaryngology, Rigshospitalet",
            "LocationCity": "Copenhagen",
            "LocationZip": "2100",
            "LocationCountry": "Denmark"
          }
        ]
      }
    },
    "IPDSharingStatementModule": {
      "IPDSharing": "No"
    }
  },
  "DerivedSection": {
    "MiscInfoModule": {
      "VersionHolder": "January 20, 2022"
    },
    "ConditionBrowseModule": {
      "ConditionMeshList": {
        "ConditionMesh": [
          {
            "ConditionMeshId": "D000009959",
            "ConditionMeshTerm": "Oropharyngeal Neoplasms"
          },
          {
            "ConditionMeshId": "D000014987",
            "ConditionMeshTerm": "Xerostomia"
          },
          {
            "ConditionMeshId": "D000012466",
            "ConditionMeshTerm": "Salivary Gland Diseases"
          }
        ]
      },
      "ConditionAncestorList": {
        "ConditionAncestor": [
          {
            "ConditionAncestorId": "D000009059",
            "ConditionAncestorTerm": "Mouth Diseases"
          },
          {
            "ConditionAncestorId": "D000009057",
            "ConditionAncestorTerm": "Stomatognathic Diseases"
          },
          {
            "ConditionAncestorId": "D000010610",
            "ConditionAncestorTerm": "Pharyngeal Neoplasms"
          },
          {
            "ConditionAncestorId": "D000010039",
            "ConditionAncestorTerm": "Otorhinolaryngologic Neoplasms"
          },
          {
            "ConditionAncestorId": "D000006258",
            "ConditionAncestorTerm": "Head and Neck Neoplasms"
          },
          {
            "ConditionAncestorId": "D000009371",
            "ConditionAncestorTerm": "Neoplasms by Site"
          },
          {
            "ConditionAncestorId": "D000009369",
            "ConditionAncestorTerm": "Neoplasms"
          },
          {
            "ConditionAncestorId": "D000010608",
            "ConditionAncestorTerm": "Pharyngeal Diseases"
          },
          {
            "ConditionAncestorId": "D000010038",
            "ConditionAncestorTerm": "Otorhinolaryngologic Diseases"
          }
        ]
      },
      "ConditionBrowseLeafList": {
        "ConditionBrowseLeaf": [
          {
            "ConditionBrowseLeafId": "M16876",
            "ConditionBrowseLeafName": "Xerostomia",
            "ConditionBrowseLeafAsFound": "Xerostomia",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M14437",
            "ConditionBrowseLeafName": "Salivary Gland Diseases",
            "ConditionBrowseLeafAsFound": "Salivary Gland Diseases",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M12037",
            "ConditionBrowseLeafName": "Oropharyngeal Neoplasms",
            "ConditionBrowseLeafAsFound": "Oropharynx Cancer",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M11171",
            "ConditionBrowseLeafName": "Mouth Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M11169",
            "ConditionBrowseLeafName": "Stomatognathic Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M12669",
            "ConditionBrowseLeafName": "Pharyngeal Neoplasms",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M12114",
            "ConditionBrowseLeafName": "Otorhinolaryngologic Neoplasms",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M8500",
            "ConditionBrowseLeafName": "Head and Neck Neoplasms",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M12667",
            "ConditionBrowseLeafName": "Pharyngeal Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M12113",
            "ConditionBrowseLeafName": "Otorhinolaryngologic Diseases",
            "ConditionBrowseLeafRelevance": "low"
          }
        ]
      },
      "ConditionBrowseBranchList": {
        "ConditionBrowseBranch": [
          {
            "ConditionBrowseBranchAbbrev": "BC07",
            "ConditionBrowseBranchName": "Mouth and Tooth Diseases"
          },
          {
            "ConditionBrowseBranchAbbrev": "All",
            "ConditionBrowseBranchName": "All Conditions"
          },
          {
            "ConditionBrowseBranchAbbrev": "BC04",
            "ConditionBrowseBranchName": "Neoplasms"
          },
          {
            "ConditionBrowseBranchAbbrev": "BC09",
            "ConditionBrowseBranchName": "Ear, Nose, and Throat Diseases"
          }
        ]
      }
    }
  }
}